ATHA vs. IMNN, CLNN, OSTX, ANEB, BRNS, RNTX, BDRX, AADI, QNTM, and RVPH
Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Imunon (IMNN), Clene (CLNN), OS Therapies (OSTX), Anebulo Pharmaceuticals (ANEB), Barinthus Biotherapeutics (BRNS), Rein Therapeutics (RNTX), Biodexa Pharmaceuticals (BDRX), Aadi Bioscience (AADI), Quantum Biopharma (QNTM), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry.
Athira Pharma vs. Its Competitors
Imunon (NASDAQ:IMNN) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.
Imunon presently has a consensus target price of $15.50, indicating a potential upside of 839.39%. Athira Pharma has a consensus target price of $13.83, indicating a potential upside of 4,104.66%. Given Athira Pharma's higher probable upside, analysts plainly believe Athira Pharma is more favorable than Imunon.
Imunon received 5 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 89.29% of users gave Imunon an outperform vote while only 54.05% of users gave Athira Pharma an outperform vote.
Athira Pharma's return on equity of -115.62% beat Imunon's return on equity.
In the previous week, Imunon had 3 more articles in the media than Athira Pharma. MarketBeat recorded 7 mentions for Imunon and 4 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.89 beat Imunon's score of 0.70 indicating that Athira Pharma is being referred to more favorably in the news media.
Imunon has higher revenue and earnings than Athira Pharma. Imunon is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
4.5% of Imunon shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 5.0% of Imunon shares are held by insiders. Comparatively, 22.1% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Imunon has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500.
Summary
Imunon beats Athira Pharma on 9 of the 17 factors compared between the two stocks.
Get Athira Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athira Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ATHA) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy ATHA Stock Free ATHA Stock Alerts